For more information, visit our Benign Hematology Program
Return to Cancer Program Name Search
Title: Novel Mechanism for Cancer Associated Thrombosis
Brief Title: Multiomic Analysis of CAT
For info regarding 25-524
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia
Brief Title: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Brief Summary: The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well
patients respond to this investigational treatment. NVG-2089 is a new drug that is being
developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a
protein called IVIg. NVG-2089 is designed to help the immune system by attaching
(binding) to certain receptors in the body and activating them, which helps reduce
inflammation and supports how the immune system works.
For info regarding 25-417
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Evaluating Platelet Drp1 Phosphorylation in Patients With Heparin Induced Thrombocytopenia
Brief Title: Evaluating Platelet Drp1 Phosphorylation in Patients With HIT
For info regarding 25-085
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Splanchnic Venous Thrombosis Outcomes in patients with Myeloproliferative Neoplasms
Brief Title: Splanchnic Venous Thrombosis Outcomes in Myeloproliferative Neoplasms
For info regarding 23-243
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: A Phase 2 study of ruxolitinib in low-risk essential thrombocythemia and polycythemia vera with significant symptom burden
Brief Title: Ruxolitinib in Thrombocythemia and Polycythemia Vera
Brief Summary: This research is being done to see if the drug ruxolitinib is effective in reducing the
symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- This research study involves the study drug Ruxolitinib.
For info regarding 20-364
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer
Brief Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Brief Summary: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with
Gastrointestinal, Pancreatic, or Colorectal Cancer
For info regarding 19-685
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu
Title: Hemorrhagic complications with therapeutic enoxaparin in patients with brain metastases
Brief Title: HEMRRHAGIC COMPLICATIONS IN PTS WITH BRAIN METS
For info regarding 14-058
please contact Cancer Clinical Trials at 617-975-7403 or
cancerclinicaltrialsinfo@bidmc.harvard.edu